Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P A Fasching

Showing results (81-90 of 109) with videos related to

Pageof 11
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 8, 2021
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survivalD J Slamon, P Neven, S Chia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 20, 2021
Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024]D J Slamon, P Neven, S Chia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 20, 2022
Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288]S Loibl, M Untch, N Burchardi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 25, 2020
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)P A Fasching, T Link, J Hauke, et al.
Geburtshilfe Und Frauenheilkunde|September 2, 2016
The International Endometriosis Evaluation Program (IEEP Study) - A Systematic Study for Physicians, Researchers and PatientsS Burghaus, T Fehm, P A Fasching, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 17, 2019
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo studyS Loibl, M Untch, N Burchardi, et al.
ESMO Open|November 30, 2025
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survivalJ Crown, D Stroyakovskii, D A Yardley, et al.
Acta Psychiatrica Scandinavica|April 7, 2017
Prenatal and adult androgen activities in alcohol dependenceB Lenz, C Mühle, B Braun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2025
Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapyE L Mayer, F-C Bidard, Y H Park, et al.
Geburtshilfe Und Frauenheilkunde|July 14, 2015
Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015)M Untch, N Harbeck, J Huober, et al.
Pageof 11

Showing results (81-90 of 109) with videos related to

Sort By:
Pageof 11
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 8, 2021
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survivalD J Slamon, P Neven, S Chia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 20, 2021
Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024]D J Slamon, P Neven, S Chia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 20, 2022
Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288]S Loibl, M Untch, N Burchardi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 25, 2020
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)P A Fasching, T Link, J Hauke, et al.
Geburtshilfe Und Frauenheilkunde|September 2, 2016
The International Endometriosis Evaluation Program (IEEP Study) - A Systematic Study for Physicians, Researchers and PatientsS Burghaus, T Fehm, P A Fasching, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 17, 2019
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo studyS Loibl, M Untch, N Burchardi, et al.
ESMO Open|November 30, 2025
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survivalJ Crown, D Stroyakovskii, D A Yardley, et al.
Acta Psychiatrica Scandinavica|April 7, 2017
Prenatal and adult androgen activities in alcohol dependenceB Lenz, C Mühle, B Braun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2025
Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapyE L Mayer, F-C Bidard, Y H Park, et al.
Geburtshilfe Und Frauenheilkunde|July 14, 2015
Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015)M Untch, N Harbeck, J Huober, et al.
Pageof 11